Background The consensus molecular subtypes (CMSs) of colorectal cancer (CRC) capture
tumor heterogeneity at the gene-expression level. Currently, a restricted number of …

T cell-mediated immune therapies have emerged as a promising treatment modality in
different malignancies including colorectal cancer (CRC). However, only a fraction of …

The tumor immune microenvironment (TIME) is associated with tumor prognosis and
immunotherapy response. Here we develop and validate a CT-based radiomics score (RS) …

Purpose: Transcriptomic profiling was performed for microsatellite instability-high (MSI-
H)/mismatch repair-deficient (dMMR) gastrointestinal tumors to determine the predictors of …

Background Lipid metabolic reprogramming in colon cancer shows a potential impact on
tumor immune microenvironment and is associated with response to immunotherapy …

While colorectal cancers (CRC) are paradigmatic tumors invaded by effector memory
lymphocytes, the mechanisms accounting for the relative resistance of MSI negative CRC to …

Neoadjuvant chemoradiotherapy (NACRT) or chemotherapy (NACT) followed by radical
resection and then adjuvant therapy is considered the optimal treatment model for locally …

Background: N6-methyladenosine (m6A), 5-methylcytosine (m5C) and N1-methyladenosine
(m1A) are the main RNA methylation modifications involved in the progression of cancer …

Purpose The molecular pathogenesis of solid tumour was first assessed in colorectal cancer
(CRC). To date,≤ 100 genes with somatic alterations have been found to inter-connectively …

Immunotherapy has transformed treatment for various types of malignancy. However, the
benefit of immunotherapy is limited to a minority of patients with mismatch-repair-deficient …